As mentioned, SLE diagnosis relies on composite data from clinical manifestations and biomarkers such as serum autoantibodies (anti-dsDNA or anti-nucleosome) or complement (C3/C4) levels. This evidence concerns the gene C4A and systemic lupus erythematosus.